Progress of immunotherapy in the first-line treatment of advanced non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2019.03.014
- VernacularTitle:免疫治疗在晚期非小细胞肺癌一线治疗中的研究进展
- Author:
Xin FANG
1
;
Yan YU
;
Qingwei MENG
;
Zonglin JIAO
Author Information
1. 哈尔滨医科大学附属肿瘤医院内六科 150081
- Keywords:
Carcinoma,non-small-cell lung;
Immunotherapy;
Programmed death 1;
Programmed death ligand 1
- From:
Cancer Research and Clinic
2019;31(3):198-201
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,immunotherapy has gradually become a new treatment method of neoplasms,and the patients with solid tumors can benefit from immunotherapy.Immunotherapy has also been used in the treatment of non-small cell lung cancer (NSCLC),which shows a remarkable effect.At present,programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have achieved obvious effects in the treatment of NSCLC.With the continuous study of clinical trials,immunosuppressants have obtained indications in the first-line and second-line treatment of advanced NSCLC.This new treatment changes the treatment mode of lung cancer,and it also brings challenges for the treatment of efficacy evaluation and treatment-related adverse reactions of the tumors.This review summarizes the progress of immunotherapy as the first-line treatment of patients with advanced NSCLC.
